Supply of medicines: paternalism, autonomy and reality

David Prayle and Margaret Brazier
Universities of Manchester and Liverpool, and University of Manchester

Abstract
Radical changes are taking place in the United Kingdom in relation to the classification of, and access to, medicines. More and more medicines are being made available over the counter both in local pharmacies and in supermarkets. The provision of more open access to medicines may be hailed as a triumph for patient autonomy. This paper examines whether such a claim is real or illusory. It explores the ethical and legal implications of deregulating medicines. Do patients benefit? What is the impact on pharmacists? Are the true beneficiaries of change largely the pharmaceutical industries?

(Journal of Medical Ethics 1998;24:93–98)

Keywords: Access to medicines; autonomy and paternalism; deregulation; pharmacy

Introduction
A silent revolution is taking place in the United Kingdom. Driven partly, though not exclusively, by European Community legislation,1 the government is re-classifying a rapidly increasing number of medicines. Medicines previously available only on prescription from a medical practitioner are now being made available in pharmacies to be bought over the counter under the supervision of a pharmacist. Medicines traditionally accessible only in pharmacies are likewise being re-classified to be included in the general sales list which allows them to be purchased in any supermarket or garage shop. Commentary on the implications of the process for health care practice has been forthcoming in medical and pharmacy journals.2 Analysis of the ethical and legal implications of change has been sparse.

A favourable response to the re-classification of medicines might be that the more freely available a medicine, the greater the autonomy of the patient. However, if we can choose to purchase medicines then we are not patients but customers. Such a superficial analysis is incomplete. The most dramatic change in the status of medicines in Britain has not yet been to make medicines entirely freely available but to allow sales of certain products in pharmacies. The pharmacist assumes the mantle of professional intermediary formerly worn in most cases by the general practitioner. Deregulation is far from whole-hearted, raising no more than two cheers for autonomy.

Deregulation of medicines also prompts the question whether paternalism is necessarily all bad? Given the inherent risks of medicines, is the presence of a professional to advise and inform the layperson a prerequisite of beneficence in the supply of medicines? May professionals on occasion have a duty to restrict access to medicines and to play a role as gatekeepers as well as advisers?

This paper examines the classification of medicines in the light of European legislation. Having sketched in the background, the ethical implications of enhancing access to medicines will be explored from the perspective of patients. The impact on the legal and ethical responsibilities of professionals, primarily pharmacists, will be debated. Finally, we seek tentatively to consider whose interests really benefit from change. Are the winners patients who rejoice in an enhanced autonomy, pharmacists luxuriating in a new professional status, or the government and the pharmaceutical companies each in their own way benefiting economically from a process which it is hoped may drive down National Health Service (NHS) costs3 yet still increase the overall profit from sales of medicines? We suggest that the picture emerging from an analysis of deregulation of medicines is one of confusion.

Re-classifying medicines
The classification of medicines lies at the heart of provisions within the (British) Medicines Act 1968. Medicines are divided into three distinct categories. The primary purpose of classification is to promote the safe use of medicines. A Prescription Only Medicine (POM) can normally only be supplied on prescription after patients consult a medical practitioner.4 Medicines which are freely available to the public in any normal retail outlet are placed on the General Sales List (GSL). Such medicines will be pre-packaged items, for example, small packs of paracetamol tablets. Unusually, but not exclusively, in the
have carried out the survey.\(^5\) The implications for pharmacists, pharmacy (P) medicines. Access to P medicines is therefore dependent on the supervision of a pharmacist. As with POM medicines, a professional intermediary controls the consumer’s access to medicines and is available to offer expert advice on its suitability.

The classification of a medicine is set out in its product licence.\(^7\) The criteria determining a medicine’s classification as POM, P or GSL include safety, efficacy, pharmacology and toxicology, the product literature available to users, data on side effects, drug interactions and any potential for abuse of the product.\(^8\) For over twenty years after the enactment of the 1968 act, British regulators adopted an extremely cautious approach to the re-classification of medicines. From 1991 a change of attitude can be detected,\(^9\) a change driven further forward by a 1992 directive from the European Community on the classification of medicines throughout the Community.\(^1\) That EC directive sets out principles governing the classification of medicines to be available with or without prescription,\(^10\) based mainly on safety grounds, but in essence having a pro-deregulation bias. The directive further requires that a mandatory five-yearly review of classification takes place, facilitated by the British regulators, who have undertaken to complete the process of re-classification within twelve months of any request from a manufacturer.\(^11\)

The result of European intervention and the radically altered attitude of British regulators to categorising medicines is this: more and more medicines of greater potency are available for purchase in pharmacies and in ordinary retail outlets.\(^12\)

Three principal motivations for change can be identified. First, the Pharmaceutical Society, representing and regulating pharmacists, pressed for greater availability of medicines in pharmacies, i.e. changes from POM to P status. Making more medicines available over the counter in pharmacies was perceived as an extension of the pharmacist’s professional role. The society has published lists of medicines which it believes should be released to the control of the pharmacist and commentators suggest that its recommendations have carried weight.\(^13\) Paradoxically the Pharmaceutical Society more recently has expressed disquiet about the speed and extent of deregulation when medicines are given GSL status. Concern has been voiced about the rapid dual re-classification of ibuprofen, a powerful pain-killer, first from POM to P status then from P to GSL.\(^13\)

Second, the government has sought to promote change, partly as an integral element in its general policy of deregulation but also to drive down costs in the NHS drug budget. When a medicine moves to P status it is hoped more and more patients will simply purchase the product themselves, saving the cost to the NHS of certain prescriptions and saving expensive general practitioner (GP) time.

Third, the pharmaceutical industry has an obvious and powerful interest in re-classification. Increased sales of P and GSL medicines can be expected, particularly as such medicines, unlike POM medicines, can be advertised to the general public. As a number of previously profitable POM medicines reach the stage when patent protection expires, the manufacturer must seek means of combating competition from generic copies. Altering the medicine’s status to P and enthusiastically advertising the product under its tried and tested brand name is a useful strategy to maintain, if not increase, sales figures.

Many different sorts of medicines have already been deregulated from POM status. Potent vaginal thrush remedies and powerful antacids are now available in pharmacies. The Pharmaceutical Society has pressed for antibiotic eye-drops and creams and certain anti-emetics to move to P status.\(^14\) There is a current debate about making hormonal emergency contraception available over the counter in pharmacies.\(^15\) A brave new world of more open access to medicines beckons. Should it be applauded?

**Autonomy and access to medicines**

A restrictive approach to access to medicines restricts individual autonomy. The longer the list of POM medicines, the less able individuals are to control their own health status via self-diagnosis and self-medication. People are compelled to seek medical assistance and doctors are empowered to control access to medication. Reducing the list of POM medicines might be seen as enhancing autonomy. The flaw in this approach derives from the anomalous P category of medicines.\(^16\) They can be purchased, but only from a pharmacy under the supervision and control of a pharmacist. Persons seeking a P medicine must in theory submit to an interrogation from the pharmacist (or his assistant) about their familiarity with the drug, their medical history and their potential use of the product.\(^17\) This “consultation” may well take place before an audience of other customers.\(^18\) If the pharmacist is not satisfied that
the customer will use the medicine sought properly, he or she may, indeed must, refuse to sell.

What justification can there be for allowing a "retailer" to police his customers' purchasing habits? Two arguments may be advanced. First, it may be contended that controlling access to P medicines is necessary to prevent harm to others. Second, it may be, and is, maintained that unrestricted access to medicines may endanger the customer.

Preventing harm to third parties is a well recognised ground for limiting autonomy.19 It cannot however be consistently advanced as the rationale for the P medicine category. Quantities of paracetamol large enough to kill have for years been available in normal retail outlets on the GSL list. Antibiotics might arguably be kept on restricted access because if antibiotics are abused and antibiotic bacterial resistance develops, our health state could endanger others.20 The vast majority of P medicines fall into two classes. There are medicines which are effective but carry some risk of morbidity. That risk is enhanced if the medicine is used incorrectly, either in overdose or if the customer has misdiagnosed his original condition.21 Then there are medicines where the risk of morbidity is minimal but the pharmacological efficacy may be equally minimal.

The pharmacist, it might be suggested, protects the customer from self-harm either from an inherent risk in the medicine or from buying a largely useless remedy. But why should the law intervene with such benevolent paternalism to protect the purchaser of a medicine? Rarely, other than in relation to the purchase of goods classified as medicines does the state see fit to monitor our habits so intensively and intrusively, at any rate if we are adults.

Justifying moderate paternalism?

Self-harm per se may be regarded as an insufficient justification for limiting the freedom of a person capable of making autonomous choices. Discussion of patient autonomy has, however, tended to focus on what patients may prevent health professionals doing to them rather than what they may demand that health professionals do. Evaluating the role of the pharmacist and the category of P medicines requires that we analyse the concept of autonomous choice of medicines, and explore the rights and interests of pharmacists themselves.

Autonomous choice depends on the provision of the necessary information on which to base that choice. People can only make maximally autonomous choices if the following conditions are met: the information requisite to make an accurate self-diagnosis is available; there is an understanding of the correct use of a product, and there is an awareness of any potential risks and side effects of available remedies. Pharmacists selling medicines are constrained by both an obligation of beneficence and non-maleficence and by respect for autonomy and should offer appropriate information. This ethical obligation as health professionals prevents the simple handing over of goods regardless of the patient's welfare.

Conventional principles of health care ethics lead fairly readily to the conclusion that pharmacists are entitled to act as professional intermediaries in the supply of medicines. Providing information and advice in no way restricts autonomy. More problematic is their role as gatekeeper of P medicines. Should pharmacists refuse to supply medicines to customers fully aware of the potential risks and side effects of the product and accurately informed of the dangers of misuse? Should pharmacists be empowered to question customers' self-diagnoses and deny access to medicines judged inappropriate or dangerous?

Pharmacists claim with some force that they are not simply shopkeepers but professionals. While a medicine remains on the POM list medical practitioners can prevent access to that medicine whatever the desire of their patients. The courts in England have always refused to compel doctors to act in a manner contrary to their clinical judgment as long as that judgment conforms to responsible professional practice.22 To deny the same discretion in judgment to the pharmacist is to reject the professional status of pharmacists, or at least to declare that while doctors are professionals "first class", pharmacists are professionals "second class". Moreover the very purpose of the medicines legislation which confers powers on pharmacists to restrict access to P medicines is to ensure professional protection of the public from dangerous medicines. Medicines, society has determined are different from other goods. The impact of illness, even minor illness, and the fears generated by ill-health result in a degree of vulnerability even on the part of a normally robust and rational person. Moderate paternalism is justifiable.

Pharmacists at risk

So far we have examined the impact of changes in the supply of medicines on patients. To understand the full implications of those changes their implications for the legal and ethical responsibilities of community pharmacists must also be explored. Pharmacists have not faced the tide of litigation against them that doctors have.23 As more and more medicines pass to their control, may the picture change? A recent survey showed
that 25% of claims against medical practitioners related to medication errors. What is the legal position where injury or loss results from a P medicine sold over the counter?

Doctors prescribing, and pharmacists dispensing, drugs owe a duty of care to their patients. They will be held responsible if they fail to exercise their professional judgment in the provision of the medicine to the patient. Their legal obligation is to act carefully and professionally. But the pharmacist selling a medicine in effect and within certain limits guarantees the safety and efficacy of that product. The Sale of Goods Act 1979 implies into every business contract for the sale of goods (which in this context indubitably includes medicines) conditions that the goods are of satisfactory quality and fit for the purpose for which they were sold. Liability is strict. It is no answer to a claim by a person injured by an unsafe medicine sold to him that the pharmacist exercised all reasonable care in supplying the medicine. If a drug proves to be defective the pharmacist will be liable, albeit she had no means of knowing of any latent defect in the medicine supplied by her.

Exactly what that professional obligation entails in terms of contractual guarantees of fitness for purpose is difficult to tease out. Medicines are more complex than everyday goods. A young girl comes into a pharmacy and asks for a branded remedy for vaginal thrush. In fact she is suffering from a sexually transmitted disease. The pharmacist simply sells her the medicine. Was the medicine fit for the purpose? It was fit for the purpose the girl believed she needed it for but not for her true condition. A man asks for a powerful painkiller for a “hell of a hangover”. He is sold ibuprofen. Unfortunately he is asthmatic and succumbs to a near fatal attack of asthma. A mother takes her child into the pharmacy. The child has a temperature of 103°F, has been sick, and is visibly distressed. The pharmacist sells a harmless but useless cough mixture.

What of the medicine positively dangerous for that patient?

In such a case the crux of the matter becomes, given the nature of the medicine, does fitness for purpose demand that the pharmacist explore the purpose of his customer. The legal reality becomes that the guarantee inherent in the contract may for the pharmacist be little different from his professional obligation of care. If he fails to comply with good practice requiring that he checks that the young girl has a condition making the use of her chosen medicine appropriate, if he does not seek to ensure that the man with the hangover does not have a condition contra-indicating ibuprofen, or fails to tell mum to take her child to the doctor he is negligent. He is in breach of his professional duty of care.

Medicines Act

What is less clear is just how far a pharmacist must go to discharge that professional duty. Does a pharmacist meet his legal obligation by seeking to provide the necessary advice and information to the girl who believes mistakenly that she has thrush, to the asthmatic with the hangover and the mother of the feverish child? They may refuse to follow such advice, or angrily reject any cross-examination or interference. Should pharmacists, are they required to, refuse to sell medicines which customers want but which they believe to be unsafe for the recipients? Will the law enforce a gatekeeper role? No simple uniform answer can be given. If the medicine sought is a P medicine then it can be argued that the Medicines Act expressly imposes on pharmacists a responsibility to protect patients even against themselves. A court adjudicating on a patient’s claim that the pharmacist acted negligently in supplying her with the medicine would be unlikely to find that a practice which breached the act constituted responsible professional conduct. The patient’s own conduct in insisting on being given the product might reduce the level of compensation payable to her, by way of a plea of contributory negligence, but would not entirely exculpate the pharmacist. Where a medicine is on general sale, as ibuprofen is, it is more difficult to sustain an argument that pharmacists must refuse to sell the medicine or risk liability for professional negligence. The dissatisfied customer can simply walk out of the pharmacy and buy ibuprofen at a local supermarket. The sick child raises slightly different issues. Does the pharmacist have a duty to the child to protect her from her mother’s folly? However, again any enforced gatekeeper role may be futile. Mother too can simply pick up the GSL medicine from a supermarket shelf. The law, we would sug-
gest, incorporates into the pharmacist’s duty of care an obligation to protect patients from unsafe or inappropriate P medicines, but no more than an obligation to advise patients sufficiently to protect themselves in relation to GSL medicines. It might be asked why even an obligation to advise applies to GSL medicines, given their free availability elsewhere. The answer is that in resorting to a pharmacy, rather than their local supermarket to buy medicines, patients enter the pharmacy with an expectation of receiving professional service.

The pharmacists’ dilemma in reconciling theory and reality on the shopfloor is likely to be exacerbated by two current, and contradictory developments.

First, the price of licensed medicines is at present protected by a resale price maintenance agreement, that is to say, manufacturers fix a price which retailers cannot choose to undercut. In practice that means the law prohibits supermarkets cutting the price of GSL medicines so as to attract custom away from pharmacies and enhance volume sales of such products. The justification for such an anti-competitive practice has been to protect local pharmacies, not solely for the benefit of the pharmacists, but to ensure the public’s continued access to professional advice on self-medication. Now an application is before the courts to abolish resale price maintenance for medicines, opening the door to competition in relation to GSL medicines and making it yet more difficult for pharmacists to fulfil an advisory function in selling medicines. Why pay more for a medicine and have to justify your purchase?

A second current development apparently seeks to restore some force to the pharmacist’s role as protector of the public. The Medicines Control Agency (MCA), responding to concern about paracetamol overdoses, has issued for consultation proposals to limit the availability of over-the-counter painkillers by restricting pack sizes available both in pharmacies and general sales outlets. Such painkillers will be available on the GSL list only in packs of 12. Up to 30 tablets will normally be available from pharmacies but pharmacists will be permitted to sell up to 100 tablets to patients with recurrent or chronic conditions, if the pharmacist judges such a sale to be appropriate.

Mere functionaries
This description proves superficial, however, when we examine paracetamol, for example. The risk of overdose is real. An overdose of 15 paracetamol tablets can cause irreversible liver damage, turning an impulsive action into a death sentence. Will the MCA proposal protect such vulnerable, suicidal people? If paracetamol remains on the GSL list at all, what is to prevent such a person collecting up several packs of 12? Meanwhile the patient in need of the medicine and intending to use it properly has restricted access to it, and, particularly if the resale price maintenance agreement goes, must pay more for a compulsory visit to the pharmacy. Pharmacists enabled to sell more than a couple of days’ supply are found again impaled on the horns of the dilemma of how far theirs is a policing rule. Can
they effectively determine to whom it is appropriate to sell a pack of 100 tablets?

The overall impact of this picture of deregulation (and re-regulation) of medicines is that, for the most part, selling medicines is becoming increasingly commercial. Unsurprisingly customers come to perceive themselves as consumers not patients. The pharmacist, or the assistant, are mere functionaries whose task is to supply the product that customers, aided by the manufacturers' advertising agents, have determined they desire. Professional ethics fade into irrelevance. Beneficence becomes impossible to deliver. Who benefits from this brave new world? It seems doubtful that patients will. They lose a source of skilled advice on medicines, confront risks in self-medication which they may not fully comprehend and may waste money on marginally useful medicines. Pharmacists stand to lose a great deal. Reduced to mere retailers their professionalism is threatened. “forced” to comply with demands of consumerism their pockets will ultimately suffer as litigation proliferates. The manufacturers of medicines may rejoice. Creating a climate where medicines may be marketed like any other consumer goods, profits should rise.

So the heart of the question becomes: are medicines different from other consumer goods? Why should paracetamol be policed in a way alcohol is not? Why should aspirin be treated differently from insecticide? It may be argued that the answer should be that medicines are no different from other goods. In that case the whole edifice of the regulation of medicines needs re-thinking, and concepts of professional ethics current amongst all health professionals, including pharmacists, must be converted into concepts of business ethics alone.

David Prayle, BSc(Pharm), MSc, MRPS, is a Research Fellow at the Institute of Medicine, Law and Bioethics, Universities of Manchester and Liverpool. Margaret Brasier, LLB, is a Barrister and Professor of Law at the University of Manchester and a Director of the Institute of Medicine, Law and Bioethics.

References and notes
1 Council directive 92/26/EEC. Classification for the supply of medicinal products for human use.
3 But see doubts expressed by Maynard A, Richardson J. Over the counter medicines. Social Market Foundation occasional paper, 1996.
4 See British National Formulary: exceptionally, emergency supplies of a POM may be made by a pharmacist at a patient's request. It must be impractical to obtain a prescription and normally only a maximum of five days' supply of the medicine may be made.
5 Canada, France, Germany and Switzerland also have three categories of medicines. Australia has four. In the USA there are only two categories, the equivalent of POM and GSL, although there is support for a third. See Madahavan S. Factors influencing pharmacists' preference for the legal classification of Rx - to - OTC switched drug products. Journal of Clinical Pharmacy and Therapeutics 1993;18:281-90.
6 This default category consists of medicines not listed as being GSL or POM, ie there is no list of P medicines.
9 See reference 2: Blenkinsopp and Bradley: 630.
13 See reference 2: Blenkinsopp and Bradley: 835.
14 See reference 7: 545.
20 Orally there are proposals to deregulate antibiotic creams and eye drops. See reference 18.
22 R v (a minor) (wardship: medical treatment) [1992] 4 All E.R 619, CA.
Supply of medicines: paternalism, autonomy and reality.
D Prayle and M Brazier

doi: 10.1136/jme.24.2.93

Updated information and services can be found at:
http://jme.bmj.com/content/24/2/93

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/